FindTrial
Sign In

MANP

DRUG4 trials

Sponsors

Mayo Clinic, E-Star BioTech, LLC, Horng Chen

Conditions

Chronic Kidney DiseasesDifficult to Control HypertensionHeart Failure With Preserved Ejection FractionHypertensionMetabolic SyndromeResistant Hypertension

Phase 1

MANP in Hypertension and Metabolic Syndrome
CompletedNCT03781739
Mayo ClinicHypertension, Metabolic Syndrome
Start: 2017-08-18End: 2019-12-10Updated: 2020-11-13
Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
CompletedNCT05247528
E-Star BioTech, LLCDifficult to Control Hypertension, Resistant Hypertension
Start: 2021-12-20End: 2022-10-31Updated: 2022-11-29
Enhancing the Natriuretic Peptide System in HFpEF
Enrolling by invitationNCT05279742
Horng ChenChronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction
Start: 2022-11-04End: 2027-04-30Target: 60Updated: 2025-10-09

Phase 2

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
RecruitingNCT06343298
E-Star BioTech, LLCDifficult to Control Hypertension
Start: 2024-11-17End: 2026-09-01Target: 120Updated: 2025-10-06

Related Papers

MANP: A natriuretic peptide-based therapy for cardiometabolic disease
2024-03-26
MANP in Hypertension With Metabolic Syndrome
JACC Basic to Translational Science2023-11-018 citations
Cardiovascular and metabolic effects of MANP. a novel GC-A activator, in human hypertension with metabolic syndrome
European Heart Journal2023-11-01